Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Vectura Group Company

VEC.L
GB00BKM2MW97
A2PTCY

Price

0
Today +/-
-0
Today %
-0 %
P

Vectura Group stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Vectura Group stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Vectura Group stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Vectura Group stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Vectura Group's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Vectura Group Stock Price History

DateVectura Group Price
10/18/20210 undefined
10/15/20210 undefined

Vectura Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Vectura Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vectura Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vectura Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Vectura Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Vectura Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Vectura Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vectura Group’s growth potential.

Vectura Group Revenue, EBIT and net profit per share

DateVectura Group RevenueVectura Group EBITVectura Group Net Income
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
2023e0 undefined0 undefined0 undefined
2022e0 undefined0 undefined0 undefined
2021e0 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined
20030 undefined0 undefined0 undefined
20020 undefined0 undefined0 undefined
20010 undefined0 undefined0 undefined

Vectura Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200120022003200420052006200720082009201020112012201320142015201620172018201920202021e2022e2023e2024e2025e
3324814253140423330365872126148160178190177194203212227
---33.33100.00100.0075.0078.5724.0029.035.00-21.43-9.0920.0061.1124.1475.0017.468.1111.256.74-6.849.604.644.437.08
33.3333.3350.0075.0075.0071.4380.0087.1090.0095.2490.9196.6797.2294.8394.4466.6760.8161.2553.3753.16-----
11136102027364030293555688490989510100000
-2-7-8-9-8-11-24-20-15-10-13-11-3-70-35-83-54-152300000
-66.67-233.33-400.00-225.00-100.00-78.57-96.00-64.52-37.50-23.81-39.39-36.67-8.33-12.07--27.78-56.08-33.75-8.4312.11-----
-2-5-8-7-6-6-19-16-10-8-4-5-235-32-85-88-221224053464853
-150.0060.00-12.50-14.29-216.67-15.79-37.50-20.00-50.0025.00-60.00-250.0066.67-740.00165.633.53-75.00-654.55-67.2132.50-13.214.3510.42
34.847.758.782.3100143.3291.5295.9297.3300.3304307.3311.8379.94383.45562.06626.68614.86651.9608.400000
-------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Vectura Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Vectura Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20012002200320042005200620072008200920102011201220132014201520162017201820192020
                                       
7.98.42.118.416.877.578.87464.174.475.570.181.79099.892.5103.7108.274.178.6
0.60.50.60.74.22.12.91.42.120.80.14.416.21.621.124.625.229.2174.7
0.20.10.10.10.20.60.318.23.75.44.94.33.479.73.83.810.219.6
000000.20.20.100.20.70.810.90.718.423.426.727.728.8
0.1000.10.35.52.8443.53.54.258.313.625.85.76.34.93.9
8.892.819.321.585.98580.578.483.885.980.196.4118.8122.7167.5161.2170.2146.1305.6
0.94.13.63.14.15.63.43.532.96911.611.511.654.853.157.855.156.4
00.40.40.401.51.20.40.40003.43.41.2066.80.50
0000400400400400400400400400400040000000
3.42.210072.562.452.241.630.923.417.1138.9104.392.2456.8335.4219.9164.1150.1
2.52.21.81.6274.349.649.649.649.649.649.657.356.857.4162.8161.4163.4162.2149.6
000001.9000000000.341.43.32.74.3
6.88.96.85.16.5156.2117106.19583.879.476.1211.6176163.1678.4557.3451.2384.6360.4
15.617.99.624.428242.1202186.6173.4167.6165.3156.2308294.8285.8845.9718.5621.4530.7666
                                       
1.11.10.9110.10.10.10.10.10.10.10.10.10.10.20.20.20.20.2
13.920.820.822.522.972.97777.278.178.32.22.897.499.2101.6102.3102.861.661.661.7
-2.1-7.5-15.3-1.8-7.2109.392.477.668.961.9137.2132.2130.8135.6143.1534451.7394.7329.9438.7
000000000000-1.6-13-7.641.426.3403046.2
00000000000000000000
12.914.46.421.716.7182.3169.5154.9147.1140.3139.5135.1226.7221.9237.2677.9581496.5421.7546.8
0.50.40.70.90.71.11.93.26.52.92.53.82.32.56.422.423.725.623.219.2
0.80.911.83.86.67.79.912.414.817.115.614.117.118.631.125.528.820.919.6
00004.74.85.910.23.36.54.60.40.626.82.216.620.717.718.845.2
00000000000000000000
0.20.80.80.103.60.91.200000000.20.20.21.21.2
1.52.12.52.89.216.116.424.522.224.224.219.81746.427.270.370.172.364.185.2
0.21.40.70015.27.95.400000004.33.93.86.43
1.1000021.8004.13.10.3033.923.720.476.853.535.728.427.2
00002.36.98.21.8001.31.330.41.5117.312.515.312.46.2
1.31.40.702.343.916.17.24.13.11.61.364.325.221.498.469.954.847.236.4
2.83.53.22.811.56032.531.726.327.325.821.181.371.648.6168.7140127.1111.3121.6
15.717.99.624.528.2242.3202186.6173.4167.6165.3156.2308293.5285.8846.6721623.6533668.4
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Vectura Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Vectura Group's financial health and stability.

Assets

Vectura Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Vectura Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Vectura Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Vectura Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200120022003200420052006200720082009201020112012201320142015null20162017201820192020
-2-7-8-9-8-11-25-20-15-13-13-11-6-7-5-5-44-96-88-22122
0222031111121287822202067115916449
000000000000000000000
00125084-31160-3-101111-83-1-20-158
00000134211102664328-111
000000000000000000000
000-10-100000-4-4-300005-16
-1-4-4-4-1-6-10-3102-20832321826302024
0-300-1-20-1-1-1-4-4-2-1-1-1-2-9-12-7-13
0-3000175200-3-3-41-1-25-25-26-9-12-60
0000119530000-380-24-24-2300013
000000000000000000000
01,0000-1,00000-5,000-5,000-6,0000000000000-1,000-5,000
1060230524000205512200-13-3-16
108021049-2-6-502053122-2-3-14-45-23
----1.00--2.00-------2.00-2.00---2.00-2.00---1.00
0000000000000000000-400
70-616-1601-4-9101-511899-7114-344
000000000000000000000
000000000000000000000

Vectura Group stock margins

The Vectura Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vectura Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vectura Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Vectura Group's sales revenue. A higher gross margin percentage indicates that the Vectura Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Vectura Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Vectura Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vectura Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vectura Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vectura Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Vectura Group Margin History

Vectura Group Gross marginVectura Group Profit marginVectura Group EBIT marginVectura Group Profit margin
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
2022e0 %0 %0 %
2021e0 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %
20050 %0 %0 %
20040 %0 %0 %
20030 %0 %0 %
20020 %0 %0 %
20010 %0 %0 %

Vectura Group Stock Sales Revenue, EBIT, Earnings per Share

The Vectura Group earnings per share therefore indicates how much revenue Vectura Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vectura Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vectura Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vectura Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vectura Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vectura Group Revenue, EBIT and net profit per share

DateVectura Group Sales per ShareVectura Group EBIT per shareVectura Group Earnings per Share
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
2023e0 undefined0 undefined0 undefined
2022e0 undefined0 undefined0 undefined
2021e0 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined
20030 undefined0 undefined0 undefined
20020 undefined0 undefined0 undefined
20010 undefined0 undefined0 undefined

Vectura Group business model

The Vectura Group PLC is a British company specializing in the development of inhalable medications. The company was founded in 1997 and is headquartered in Chippenham, England. History: Initially, Vectura focused on the development of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). In 2014, the company acquired competitor Skyepharma, expanding its product range to include a wider spectrum of inhalable medications and active ingredients. Business Model: Vectura's business model is based on collaborating with its partners to develop inhalable therapies and active ingredients. The company itself acts as a service provider, offering support to the pharmaceutical industry in the development of new solutions. Vectura has a wide range of technologies and expertise to offer its customers tailored solutions. Divisions: Vectura is divided into four different business units. "Inhaled Therapies" offers solutions for inhaling medications, including inhalers equipped with special propellants to deliver the active ingredients directly to the lungs. The "Royalty-Driven Products" division includes products for which Vectura holds licenses and benefits from the sales of these products. In the "Device Services" division, the company offers development and design services for inhalable therapies. Finally, Vectura also has a research department referred to as "New Product Opportunities," where the company works on the development of new technologies and therapies. Products: Vectura's key products include treatments for asthma and COPD, such as the inhaler Flutiform and the medication Seebri. The company also offers inhalable therapies for other diseases, such as cystic fibrosis and pulmonary hypertension. In addition to medical applications, Vectura also develops more sustainable inhalers and devices that do not rely on chlorofluorocarbons (CFCs) or other environmentally harmful propellants. Conclusion: Vectura has established itself as one of the leading companies in the field of inhalable medications. The company offers tailored solutions for its customers and invests in the development of new technologies to enhance inhalation therapy. Vectura has expanded its portfolio in recent years through the acquisition of Skyepharma and aims to further expand its market position. Vectura Group is one of the most popular companies on Eulerpool.com.

Vectura Group SWOT Analysis

Strengths

Vectura Group PLC possesses several strengths that contribute to its competitiveness and success in the market:

  • Strong patent portfolio that protects its innovative inhalation products
  • Long-standing partnerships with major pharmaceutical companies
  • Expertise in respiratory drug delivery systems
  • Efficient research and development capabilities to drive product innovation
  • Global presence and distribution network

Weaknesses

Despite its strengths, Vectura Group PLC also faces certain weaknesses that pose challenges to its growth:

  • Dependency on a limited number of major partners for revenue generation
  • Reliance on a specific therapeutic area (respiratory) may limit diversification
  • Higher vulnerability to regulatory changes and approvals
  • Costs associated with research and development investment

Opportunities

Vectura Group PLC can capitalize on various opportunities to expand and improve its market position:

  • Increasing demand for respiratory medications, particularly for chronic diseases
  • Growing aging population that requires more specialized healthcare products
  • Entry into emerging markets with rising healthcare expenditures
  • Potential partnerships or collaborations for joint product development

Threats

Despite its potential, Vectura Group PLC must also be aware of the following threats that may impact its performance:

  • Fierce competition from other pharmaceutical companies in the same therapeutic area
  • Uncertainty surrounding healthcare policies and reimbursement systems
  • Rapid advancements in technology that could disrupt traditional drug delivery methods
  • Potential patent infringement challenges from competitors

Vectura Group Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Vectura Group historical P/E ratio, EBIT multiple, and P/S ratio

Vectura Group shares outstanding

The number of shares was Vectura Group in 2023 — This indicates how many shares 608.4 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vectura Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vectura Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vectura Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vectura Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vectura Group stock splits

In Vectura Group's history, there have been no stock splits.
Vectura Group does not pay out any dividends.
Vectura Group does not pay out any dividends.
Vectura Group does not pay out any dividends.
Unfortunately, there are currently no price targets and forecasts available for Vectura Group.

Vectura Group shareholders

%
Name
Stocks
Change
Date
6.57112 % Brown Capital Management, LLC40,339,4444,648,5996/14/2021
5.01174 % TIG Advisors, L.L.C.30,766,58630,766,5868/6/2021
4.44303 % BlackRock Investment Management (UK) Ltd.27,275,301-15,2179/9/2021
4.38973 % The Vanguard Group, Inc.26,948,1427,6629/1/2021
3.80442 % AXA Investment Managers UK Ltd.23,354,973-1,400,0008/5/2021
3.71156 % Aberforth Partners LLP22,784,879-6,468,6156/8/2021
3.60110 % Legal & General Investment Management Ltd.22,106,772-11,0009/15/2021
28.47488 % Philip Morris International Inc174,804,443174,804,4438/18/2021
2.54033 % Dimensional Fund Advisors, L.P.15,594,824-281,2159/3/2021
2.11960 % Berry Street Capital Management LLP13,012,00013,012,0008/10/2021
1
2
3
4
5
...
10

Most common questions regarding Vectura Group

What values and corporate philosophy does Vectura Group represent?

Vectura Group PLC represents values and a corporate philosophy centered around innovation, integrity, and patient-centricity. As a leading provider of inhaled drug delivery solutions, Vectura strives to transform patient outcomes and improve quality of life through its advanced technologies and expertise in respiratory treatments. By focusing on innovation, Vectura continuously develops and collaborates on groundbreaking inhalation therapies, addressing unmet medical needs globally. With an unwavering commitment to integrity, the company conducts its business ethically and transparently, adhering to the highest industry standards. Through its patient-centric approach, Vectura aims to empower individuals by delivering effective, accessible, and personalized respiratory care solutions.

In which countries and regions is Vectura Group primarily present?

Vectura Group PLC is primarily present in various countries and regions across the globe. The company has a significant presence in the United Kingdom where it is headquartered. Additionally, Vectura has a strong presence in Europe, with operations and partnerships in several major European countries such as Germany, France, Italy, and Spain. Moreover, the company has expanded its reach to other regions including the United States, Canada, and Asia. With its diversified presence, Vectura Group PLC is well-positioned to serve and cater to a wide range of markets and customers around the world.

What significant milestones has the company Vectura Group achieved?

Vectura Group PLC, a reputable stock company, has accomplished several significant milestones. In its rich history, Vectura has consistently demonstrated excellence and achieved remarkable success. Notably, the company has successfully developed innovative respiratory therapies, establishing itself as a key player in the pharmaceutical industry. Vectura's groundbreaking research and development efforts have led to the creation of numerous cutting-edge products aimed at addressing various respiratory conditions. Additionally, Vectura has formed strategic partnerships and collaborations with leading pharmaceutical companies, further extending its global reach. With such notable achievements, Vectura Group PLC continues to solidify its position as a trailblazing force in the pharmaceutical and stock market sectors.

What is the history and background of the company Vectura Group?

Vectura Group PLC, founded in 1997, is a leading pharmaceutical company specializing in the development and commercialization of inhalation therapies. With headquarters in Chippenham, UK, Vectura has a rich history of innovation and collaboration in the respiratory field. The company has successfully partnered with global pharmaceutical companies to deliver novel inhalation products, leveraging their expertise in formulation and device technology. Vectura's broad portfolio includes a range of inhalation therapies to treat diseases such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections. By continuously advancing their technology platforms and strategic partnerships, Vectura remains committed to improving patients' lives worldwide through innovative respiratory solutions.

Who are the main competitors of Vectura Group in the market?

The main competitors of Vectura Group PLC in the market include pharmaceutical companies such as GlaxoSmithKline (GSK), Novartis, AstraZeneca, and Boehringer Ingelheim.

In which industries is Vectura Group primarily active?

Vectura Group PLC is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Vectura Group?

The business model of Vectura Group PLC revolves around developing and commercializing innovative inhaled therapies to improve the lives of patients suffering from respiratory conditions. As a leading pharmaceutical company, Vectura focuses on the development of therapeutic products for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other respiratory illnesses. By leveraging their expertise in inhalation, formulation, and device technologies, Vectura aims to provide effective and convenient treatment options to patients worldwide. With a strong emphasis on research and development, Vectura strives to continually advance their product portfolio, partnering with pharmaceutical companies to deliver cutting-edge respiratory solutions.

What is the P/E ratio of Vectura Group 2024?

The P/E ratio cannot be calculated for Vectura Group at the moment.

What is the P/S ratio of Vectura Group 2024?

The P/S cannot be calculated for Vectura Group currently.

What is the Quality Investing of Vectura Group?

The Quality Investing for Vectura Group is 4/10.

What is the revenue of Vectura Group 2024?

The revenue cannot currently be calculated for Vectura Group.

How high is the profit of Vectura Group 2024?

The profit cannot currently be calculated for Vectura Group.

What is the business model of Vectura Group

Vectura Group PLC is a British provider of products and services in the field of inhalation technology. It is a publicly traded company listed on the London Stock Exchange and employs approximately 700 people worldwide. The company's core business includes the development and production of inhalation products for customers in the pharmaceutical industry, as well as research and development services. Vectura focuses on developing solutions to improve the delivery of active substances through inhalation. One of Vectura's main products is a special inhalation device called "Akita," which allows for controlled and effective administration of medication directly to the lungs. The Akita system is used by many pharmaceutical companies to develop their own inhalable medications. In addition, Vectura offers support in the form of formulation and analytics services, focusing on the development and optimization of inhalation preparations, as well as conducting tests and studies on the effectiveness and safety of these products. Other business areas of Vectura include the manufacturing of specialized inhalers for customers in the animal health sector, and the development of products for the treatment of respiratory diseases such as asthma or COPD. Overall, Vectura's business model is diverse, encompassing both product development and the provision of services in the field of inhalation technology. The company specializes in the development of advanced inhalation products that enable better effectiveness and tolerability of medications. With the increasing number of respiratory diseases worldwide, Vectura's market prospects are promising. Through close collaborations with reputable pharmaceutical companies and continuous improvements in its own technologies and products, Vectura Group PLC aims to achieve strong growth and establish itself as a leading company in the field of inhalation technology.

What is the Vectura Group dividend?

Vectura Group pays a dividend of 0 GBP distributed over payouts per year.

How often does Vectura Group pay dividends?

The dividend cannot currently be calculated for Vectura Group or the company does not pay out a dividend.

What is the Vectura Group ISIN?

The ISIN of Vectura Group is GB00BKM2MW97.

What is the Vectura Group WKN?

The WKN of Vectura Group is A2PTCY.

What is the Vectura Group ticker?

The ticker of Vectura Group is VEC.L.

How much dividend does Vectura Group pay?

Over the past 12 months, Vectura Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vectura Group is expected to pay a dividend of 0 GBP.

What is the dividend yield of Vectura Group?

The current dividend yield of Vectura Group is .

When does Vectura Group pay dividends?

Vectura Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vectura Group?

Vectura Group paid dividends every year for the past 0 years.

What is the dividend of Vectura Group?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vectura Group located?

Vectura Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vectura Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vectura Group from 6/11/2021 amounting to 0.19 GBP, you needed to have the stock in your portfolio before the ex-date on 6/1/2021.

When did Vectura Group pay the last dividend?

The last dividend was paid out on 6/11/2021.

What was the dividend of Vectura Group in the year 2023?

In the year 2023, Vectura Group distributed 0 GBP as dividends.

In which currency does Vectura Group pay out the dividend?

The dividends of Vectura Group are distributed in GBP.

All fundamentals about Vectura Group

Our stock analysis for Vectura Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vectura Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.